|By PR Newswire||
|October 23, 2013 08:05 AM EDT|
NEW YORK, October 23, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Medtronic, Inc. (NYSE: MDT), Steris Corp. (NYSE: STE), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Wright Medical Group Inc. (NASDAQ: WMGI), and Synageva BioPharma Corp. (NASDAQ: GEVA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Medtronic, Inc. Research Report
On October 17, 2013, Medtronic Inc. (Medtronic) announced that it will present its CoreValve U.S. Pivotal Trial results at the 25th Annual Transcatheter Cardiovascular Therapeutics (TCT) Symposium in San Francisco on October 29, 2013. "Unveiling the CoreValve U.S. Pivotal Trial data for the first time is a significant milestone as we work toward bringing more therapy options to patients in the U.S.," said John Liddicoat, M.D., Senior Vice President, Medtronic, and President of the Medtronic Structural Heart Business at Medtronic. "This study will provide vital information for physicians and their U.S. patients, many of whom have had no good option for treating their aortic stenosis." The Full Research Report on Medtronic, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/bc94_MDT]
Steris Corp. Research Report
On October 15, 2013, Steris Corp. (Steris) announced the schedule of its earnings release and the Company will report its Q2 FY 2014 financial results before market opens on October 30, 2013. Following the release, the Company will host a conference call at 10:00 a.m. ET. The call can be accessed live over the Internet through the Company's website. The Full Research Report on Steris Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/8e31_STE]
Intercept Pharmaceuticals, Inc. Research Report
On October 8, 2013, Intercept Pharmaceuticals, Inc. (Intercept) announced the pricing of an underwritten public offering of 1.5 million shares of its common stock by certain selling stockholders at a public offering price of $62.50 per share. Further, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 225,000 shares of common stock. Intercept further reported that it will not receive any proceeds from the sale of the shares of common stock by the selling stockholders in the offering. The Full Research Report on Intercept Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/b477_ICPT]
Wright Medical Group Inc. Research Report
On October 16, 2013, Wright Medical Group, Inc. (Wright Medical) announced that it has entered into a definitive agreement to acquire Biotech International. The acquisition will significantly expand Wright's direct sales channel in France and international distribution network, with the addition of Biotech's complementary extremity product portfolio. Robert Palmisano, President and CEO of Wright, commented, "The acquisition of Biotech International is an excellent fit for our Extremities business, enabling us to immediately expand our direct foot and ankle presence in Europe and add a base of extremity revenue that we can effectively grow on a go-forward basis." The transaction is expected to close in the Q4 of 2013. The Full Research Report on Wright Medical Group Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/1782_WMGI]
Synageva BioPharma Corp. Research Report
On October 11, 2013, Synageva BioPharma Corp. (Synageva) announced 78-week results from an ongoing extension study with sebelipase alfa in adults with Lysosomal Acid Lipase (LAL) Deficiency. The Company informed that the results were presented during an oral presentation at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) annual meeting held in Chicago, Illinois. Synageva reported that six of the eight patients enrolled in the Phase 1/2 extension study completing 18 months of treatment showed sustained improvements in biochemical markers of liver damage and in the dyslipidemia associated with LAL Deficiency. The Full Research Report on Synageva BioPharma Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/8624_GEVA]
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner